DIEGO GONZALEZ

Mr. DIEGO GONZALEZ

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
RARyan Michael Antar
Ryan Michael Antar
CFChristopher Chucri Fawaz
Christopher Chucri Fawaz
DGDIEGO GONZALEZ
DIEGO GONZALEZ
VXVincent Eric Xu
Vincent Eric Xu
ADArthur Drouaud
Arthur Drouaud
MWMichael Whalen
Michael Whalen
The genetic landscape of urologic cancers has evolved with the identification of actionable mutations that impact diagnosis, prognosis, and therapeutic strategies. This narrative review consolidates existing literature on genetic mutations across key urologic cancers, including bladder, renal, prostate, upper tract urothelial, testicular, and penile. The review highlights mutations in DNA damage repair genes, such as BRCA1/2 and PTEN, as well as pathway alterations like FGFR and PD-L1 overexpression. These mutations influence tumor behavior and therapeutic outcomes, emphasizing the need for precision oncology approaches. Molecular profiling, through tools like next-generation sequencing, has revolutionized patient care by enabling targeted treatment strategies, especially in cancers with distinct molecular subtypes such as luminal or basal bladder cancer and clear cell renal carcinoma. Emerging therapies, including FGFR inhibitors and immune checkpoint blockade, offer new treatment avenues, although resistance mechanisms remain a challenge. We also emphasize the importance of biomarker identification for personalized management, especially in metastatic settings where treatment intensification is often required. Future research is needed to further elucidate our understanding of the genetics affecting urologic cancers, which will help develop novel, individualized therapies to enhance oncologic outcomes.

27 July 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
ADArthur Drouaud
Arthur Drouaud
VXVincent Eric Xu
Vincent Eric Xu
AVAlejandro Velasquez
Alejandro Velasquez
RARyan Antar
Ryan Antar
BBBrandon Boyarsky
Brandon Boyarsky
MWMichael Whalen
Michael Whalen

8 September 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
DGDIEGO GONZALEZ
DIEGO GONZALEZ
KKKris Kokoneshi
Kris Kokoneshi
SKSam Kwon
Sam Kwon
RMRyan Thomas Mathews
Ryan Thomas Mathews
RARyan Michael Antar
Ryan Michael Antar
MWMichael Whalen
Michael Whalen
Introduction: Papillary renal neoplasm with reverse polarity (PRNRP) is a rare subtype of papillary renal cell carcinoma (RCC) with unique morphology, molecular features, and good prognosis. Given its rarity, with less than 100 reported cases, further characterization is needed to enhance diagnostic accuracy and inform management strategies.Case presentation: We report the case of a 59-year-old African American female with an incidentally discovered 2.1 cm left renal mass on imaging. The patient has a medical history of hypertension, asthma, hyperlipidemia, vertigo, depression/anxiety, and prediabetes. Further evaluation via contrast-enhanced CT confirmed an enhancing renal mass without evidence of metastasis. She underwent a robotic-assisted partial nephrectomy, and postoperative pathology confirmed PRNRP with pT1aNxMxR0 staging and ISUP nuclear grade 1. Immunohistochemical analysis demonstrated positive staining for GATA3, CK7, and EMA, and Vimentin and negative for AMACR and CA IX. Molecular profiling revealed a KRAS mutation, a key feature of PRNRP. Postoperative recovery was uneventful aside from transient vertigo, and no further treatment was required.Conclusion: This case reinforces the distinct morphological and molecular profile of PRNRP, distinguishing it from other papillary RCC subtypes. The indolent behavior, absence of metastatic cases, and characteristic molecular profiling and immunohistochemical markers highlight the importance of accurate classification for optimal patient management. Furthermore, the PD-L1 positivity observed in this case raises potential implications for immune checkpoint therapy, an area warranting further investigation. As PRNRP is recently classified, continued study is essential to refine diagnostic, therapeutic, and surveillance strategies for this rare renal neoplasm.

21 July 2026 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
CSChris Staniorski
Chris Staniorski
DGDIEGO GONZALEZ
DIEGO GONZALEZ
NENatalie Ewing
Natalie Ewing
CCChristopher Corbett
Christopher Corbett
BHButool Hisam
Butool Hisam
BVBriony K. Varda
Briony K. Varda

25 July 2026 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
SKSam Kwon
Sam Kwon
DGDIEGO GONZALEZ
DIEGO GONZALEZ
FWFiona Wardrop
Fiona Wardrop
TNTali Newman
Tali Newman
JDJosiah Dallmer
Josiah Dallmer
MWMichael J. Whalen
Michael J. Whalen

20 April 2026 in Urology Case Reports
Verified
Journal Article
Open access
DGDIEGO GONZALEZ
DIEGO GONZALEZ
FRFrancis Ryan
Francis Ryan
KKKris Kokoneshi
Kris Kokoneshi
SKSam Kwon
Sam Kwon
LKLiza Khutsishvili
Liza Khutsishvili
MWMichael Whalen
Michael Whalen
Intraprostatic paraganglioma (PGL) is a rare neuroendocrine tumor arising from chromaffin cells and poses diagnostic and management challenges. We report a 63-year-old man with Grade Group 3 prostate adenocarcinoma who underwent robotic radical prostatectomy and was incidentally found to have a 1.5 mm intraprostatic PGL on final pathology. The patient had no catecholamine-related symptoms, and postoperative plasma metanephrines were normal, consistent with a nonfunctional tumor. Immunohistochemical staining supported the diagnosis. The patient elected surveillance and remains asymptomatic. This case highlights the variable presentation of prostatic PGL and emphasizes the role of pathologic evaluation, biochemical testing, and individualized management strategies.